Abstract
SAFETY AND EFFICACY OF COMBINATION OF MONTELUKAST AND LEVOCETRIZINE IN THE SYMPTOMATIC TREATMENT OF ALLERGIC RHINITIS AND ASTHMA: PHASE IV CLINICAL STUDY

Dr. Mayuresh Kiran*, Sharvari Lotankar and Lalit Pawaskar

ABSTRACT

Introduction- Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction and treatment of AR symptoms requires a stepwise approach depending on the severity and duration of symptoms. A combination of Levocetirizine which is selective, potent, oral histamine H (1) receptor antagonists and Montelukast which is a selective and orally active cysteinyl leukotriene-receptor antagonist (LTRA) is used for the treatment of Allergic rhinitis and Asthma. This Phase IV study trial evaluates the efficacy and safety of the combination of Levocetirizine and Montelukast for the treatment of Allergic Rhinitis or Allergic Asthma. Methodology- Total 270 patients were recruited for the study, of which 256 patients completed the study trial and 14 patients were lost to follow up. Assessment of the efficacy was made by the reduction in TSS and four point Likert-type scales. Safety assessment was done by analyzing the adverse events during the trial. Results- The reduction in TSS from 6.61 (baseline) to 2.94 (day 5) and 0.71 (day 10) was observed. 49 episodes of adverse events occurred and reported which were of mild intensity. Conclusion- A combination of Levocetirizine and Montelukast is safe and effective in the treatment of Allergic Rhinitis or Allergic Asthma.

Keywords: Allergic rhinitis, Asthma, Levocetrizine, Montelukast.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation

  • NEW FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2019 Issue has been successfully launched on 1 February 2019

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 4.382 to 4.918 due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT